Company Monitoring Page for Sanofi

latest headlines for company on cafepharma

Sanofi and Regeneron's Dupixent scores trial win in tough-to-treat COPD
Fierce Pharma
Thu, 03/23/23 - 11:44 am
Tags:
Sanofi, Regeneron, Dupixent, COPD, clinical trials
AAD: Will Sanofi and Regeneron’s Dupixent be a game-changer or just another antibody on the COPD scrapheap?
Fierce Pharma
Mon, 03/20/23 - 10:06 am
Tags:
Sanofi, Regeneron, Dupixent, COPD
Three's company: Sanofi follows lead of Lilly and Novo, slashes insulin price by 78% and caps out-of-pocket costs
Endpoints
Thu, 03/16/23 - 09:16 pm
Tags:
Sanofi, Lantus, insulin, diabetes, drug pricing, Eli Lilly, Novo Nordisk
Sanofi throws down $2.9B to acquire diabetes partner Provention Bio
Fierce Pharma
Mon, 03/13/23 - 10:08 am
Tags:
Sanofi, Provention Bio, M&A, diabetes
Sanders urges Sanofi, Novo Nordisk to be like Eli Lilly in reducing insulin prices
Fierce Pharma
Sun, 03/5/23 - 03:26 pm
Tags:
Eli Lilly, Novo Nordisk, Sanofi, insulin, Bernie Sanders, drug pricing
Sanofi’s clinical trial of hemophilia A therapy in children meets endpoint
Clinical Trials Arena
Sun, 03/5/23 - 03:12 pm
Tags:
Sanofi, clinical trials, hemophilia A, Altuviiio
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Yahoo/Benzinga
Wed, 03/1/23 - 07:07 pm
Tags:
Regeneron, Sanofi, FDA, Kevzara, Sarilumab, polymyalgia rheumatica
Junshi's lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Fierce Biotech
Tue, 02/28/23 - 10:03 am
Tags:
Junshi Biosciences, Amgen, Sanofi, China, clinical trials, PCSK9 inhibitors
FDA approves Sanofi’s long-lasting hemophilia drug
BioPharma Dive
Thu, 02/23/23 - 04:32 pm
Tags:
Sanofi, FDA, hemophilia A, Altuviiio
Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi
Fierce Pharma
Tue, 02/21/23 - 10:26 am
Tags:
Pfizer, RSV, vaccines, GSK, AstraZeneca, Sanofi, RSVpreF
First FDA-Approved RSV Vaccines Expected Later This Year: The Top Vaccines And Their Effectiveness
Forbes
Mon, 02/20/23 - 12:37 pm
Tags:
RSV, vaccines, GSK, Pfizer, Sanofi, Sobi, Moderna Therapeutics, AstraZeneca, JNJ, FDA
Sanofi and Regeneron face a high-risk test for Dupixent
EP Vantage
Fri, 02/17/23 - 10:20 am
Tags:
Sanofi, Regeneron, Dupixent, COPD, clinical trials
US government, Pfizer and others side with Sanofi and Regeneron in Supreme Court patent case
Endpoints
Mon, 02/13/23 - 10:12 pm
Tags:
Pfizer, Viatris, Sanofi, Regeneron, patents, Supreme Court
Reed relinquishes R&D reins at Sanofi to pursue new opportunity, sparking race to find successor
Fierce Biotech
Mon, 02/13/23 - 10:36 am
Tags:
R&D, Sanofi, John Reed
Dupixent kicks off 2023 as top pharma brand for ad impressions
Medical Devices and Diagnostics Industry
Mon, 02/6/23 - 06:13 pm
Tags:
Sanofi, Dupixent, asthma, pharma advertising
Vaccines slip, Dupixent climbs for Sanofi as it readies multiple launches in 2023
Fierce Pharma
Mon, 02/6/23 - 10:58 am
Tags:
Sanofi, Dupixent, earnings
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
BioSpace
Fri, 02/3/23 - 10:31 am
Tags:
Sanofi, tolebrutinib, myasthenia gravis
New competitors push Sanofi to offer voluntary retirement packages at two Indian sites
Endpoints
Tue, 01/31/23 - 11:20 pm
Tags:
Sanofi, India, drug manufacturing
AstraZeneca, Novo Nordisk and Sanofi score 340B-related appeals court win over HHS
Endpoints
Mon, 01/30/23 - 05:58 pm
Tags:
AstraZeneca, Sanofi, Novo Nordisk, 340B, drug discounts
Top 10 Pharma TV Ad Spenders in 2022 — Anti-Inflammatories and Diabetes Drugs Dominate
Xtalks
Sun, 01/29/23 - 01:31 pm
Tags:
television ads, pharma marketing, DTC ads, AbbVie, Rinvoq, Dupixent, Sanofi, Regeneron, Skyrizi, Novo Nordisk, Ozempic, Jardiance, Eli Lilly, Boehringer Ingelheim, Rybelsus, Trulicity, Rexulti, Otsuka, Lundbeck, Tremfya, JNJ, Verzenio

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.